Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes

Journal of Diabetes and its Complications

Volumn 21, Issue 3, 2007, Pages 137-142

  Lingvay, Ildiko ^a   Raskin, Philip ^a   Szczepaniak, Lidia S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Hepatic steatosis; Insulin treatment; Metformin; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CAPILLARY BLOOD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; FATTY LIVER; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIVER LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; HUMANS; INSULIN; MALE; METFORMIN; MIDDLE AGED; TRIGLYCERIDES;

EID: 34247593406     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.02.005     Document Type: Article

References (24)

1. Anderwald C., Bernroider E., Krssak M., Stingl H., Brehm A., Bischof M.G., Nowotny P., Roden M., and Waldhausl W. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 51 (2002) 3025-3032
2. Bajaj M., Suraamornkul S., Pratipanawatr T., Hardies L.J., Pratipanawatr W., Glass L., Cersosimo E., Miyazaki Y., and DeFronzo R.A. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52 (2003) 1364-1370
3. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., Balas B., Gastaldelli A., Tio F., Pulcini J., Berria R., Ma J.Z., Dwivedi S., Havranek R., Fincke C., DeFronzo R., Bannayan G.A., Schenker S., and Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New England Journal of Medicine 355 (2006) 2297-2307
4. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., and Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology (Baltimore, MD) 40 (2004) 1387-1395
5. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., David E., Rizzetto M., and Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. American Journal of Gastroenterology 100 (2005) 1082-1090
6. Comar K.M., and Sterling R.K. Review article: Drug therapy for non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 23 (2006) 207-215
7. Duseja A., Murlidharan R., Bhansali A., Sharma S., Das A., Das R., and Chawla Y. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis-A preliminary report. Indian Journal of Gastroenterology 23 (2004) 12-15
8. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., and Sanyal A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 41 (2005) 1313-1321
9. Longo R., Pollesello P., Ricci C., Masutti F., Kvam B.J., Bercich L., Croce L.S., Grigolato P., Paoletti S., de Bernard B., et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. Journal of Magnetic Resonance Imaging 5 (1995) 281-285
10. Luyckx F.H., Lefebvre P.J., and Scheen A.J. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss. Diabetes and Metabolism 26 (2000) 98-106
11. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., and Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358 (2001) 893-894
12. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., Inzucchi S.E., Shulman G.I., and Petersen K.F. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 (2002) 797-802
13. Nair S., Diehl A.M., Wiseman M., Farr G.H., and Perrillo R.P. Metformin in the treatment of non-alcoholic steatohepatitis: A pilot open label trial. Alimentary Pharmacology & Therapeutics 20 (2004) 23-28
14. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., Doo E., Ghany M., Premkumar A., Park Y., Liang T.J., Yanovski J.A., Kleiner D.E., and Hoofnagle J.H. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (Baltimore, MD) 39 (2004) 188-196
15. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., Grimaldi A., Capron F., and Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
16. Schwimmer J.B., Middleton M.S., Deutsch R., and Lavine J.E. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 21 (2005) 871-879
17. Sheth S.G., Gordon F.D., and Chopra S. Nonalcoholic steatohepatitis. Annals of Internal Medicine 126 (1997) 137-145
18. Siebler J., and Galle P.R. Treatment of nonalcoholic fatty liver disease. World Journal of Gastroenterology 12 (2006) 2161-2167
19. Szczepaniak L.S., Babcock E.E., Schick F., Dobbins R.L., Garg A., Burns D.K., McGarry J.D., and Stein D.T. Measurement of intracellular triglyceride stores by H spectroscopy: Validation in vivo. American Journal of Physiology 276 (1999) E977-E989
20. Szczepaniak L.S., Nurenberg P., Leonard D., Browning J.D., Reingold J.S., Grundy S., Hobbs H.H., and Dobbins R.L. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. American Journal of Physiology 288 (2005) E462-E468
21. Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., and Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
22. Toledo F.G., Sniderman A.D., and Kelley D.E. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 29 (2006) 1845-1850
23. Uygun A., Kadayifci A., Isik A.T., Ozgurtas T., Deveci S., Tuzun A., Yesilova Z., Gulsen M., and Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 19 (2004) 537-544
24. Younossi Z.M., Gramlich T., Liu Y.C., Matteoni C., Petrelli M., Goldblum J., Rybicki L., and McCullough A.J. Nonalcoholic fatty liver disease: Assessment of variability in pathologic interpretations. Modern Pathology 11 (1998) 560-565